Search

Displaying results 8201 - 8210 of 9680 in total
  1. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.

  2. Drug

    Tetrodotoxin

    go.drugbank.com/drugs/DB05232
    Investigational

    An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order tetraodontiformes, which are eaten.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    LGD2941

    go.drugbank.com/drugs/DB05234
    Experimental

    LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.

  4. Drug

    ReN001

    go.drugbank.com/drugs/DB05236
    Investigational

    ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. … ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans

  5. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been app...

    Categories: UGT2B7 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  6. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.

  7. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    the RNAi response against a targeted disease causing gene. … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid

  8. Drug

    Ronacaleret

    go.drugbank.com/drugs/DB05255
    Investigational

    Ronacaleret is a calcium-sensing receptor antagonist.

  9. Drug

    Glatiramer

    go.drugbank.com/drugs/DB05259
    ApprovedInvestigational

    Glatiramer acetate is a mix of synthetic polypeptides that includes L-glutamic acid, L-alanine, L-tyrosine, and L-lysine at an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. … [A248870] Originally, glatiramer acetate was designed as a stimulant of myelin basic protein (MBP), a myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune

    Synonyms: (T,G)-A-L
  10. Drug

    Oxypurinol

    go.drugbank.com/drugs/DB05262
    Investigational

    Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.